Botanix Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	21.92	5.79	2.07	3.77	2.75	6.88
Other Revenue	-	-	-	-	-	0.01
Revenue	21.92	5.79	2.07	3.77	2.75	6.89
Revenue Growth (YoY)	959.24%	179.74%	-45.14%	36.94%	-60.00%	-9.07%
Cost of Revenue	8.52	3.77	3.65	5.73	10.29	6.57
Gross Profit	13.39	2.02	-1.58	-1.96	-7.54	0.32
Selling, General & Admin	79.35	62.15	7.94	4.41	4.28	2.62
Other Operating Expenses	-	-	-	1.13	0.89	0.41
Operating Expenses	97.96	84.93	12.41	7.17	5.65	3.7
Operating Income	-84.56	-82.91	-13.99	-9.13	-13.19	-3.38
Interest Expense	-6.94	-5.37	-0.01	-0.08	-0.04	-0.06
Interest & Investment Income	1.4	1.88	0.08	0.07	0.04	0.1
Currency Exchange Gain (Loss)	0.03	0.01	0.06	-0.01	0.02	-0
Other Non Operating Income (Expenses)	1.37	-	-	-	-	-
Pretax Income	-88.7	-86.4	-13.87	-9.15	-13.17	-3.33
Net Income	-88.7	-86.4	-13.87	-9.15	-13.17	-3.33
Net Income to Common	-88.7	-86.4	-13.87	-9.15	-13.17	-3.33
Shares Outstanding (Basic)	1,919	1,845	1,502	1,154	973	973
Shares Outstanding (Diluted)	1,919	1,845	1,502	1,154	973	973
Shares Change (YoY)	13.48%	22.87%	30.12%	18.58%	0.02%	3.91%
EPS (Basic)	-0.05	-0.05	-0.01	-0.01	-0.01	-0.00
EPS (Diluted)	-0.05	-0.05	-0.01	-0.01	-0.01	-0.00
Free Cash Flow	-78.49	-78.87	-8.24	-12.08	-11.19	-2.98
Free Cash Flow Per Share	-0.04	-0.04	-0.01	-0.01	-0.01	-0.00
Gross Margin	61.11%	34.85%	-76.48%	-51.83%	-273.62%	4.58%
Operating Margin	-385.82%	-1432.24%	-676.11%	-241.93%	-478.66%	-49.08%
Profit Margin	-404.72%	-1492.37%	-670.20%	-242.66%	-478.10%	-48.41%
Free Cash Flow Margin	-358.13%	-1362.39%	-398.17%	-320.27%	-406.24%	-43.21%
EBITDA	-82.23	-80.65	-13.92	-9.11	-13.17	-3.36
EBITDA Margin	-	-	-	-241.38%	-	-48.84%
D&A For EBITDA	2.33	2.26	0.07	0.02	0.02	0.02
EBIT	-84.56	-82.91	-13.99	-9.13	-13.19	-3.38
EBIT Margin	-	-	-	-241.93%	-	-49.08%
Revenue as Reported	-	-	-	-	2.79	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.